TICKERNERD
Menu
HURAHURAHealthcare · Biotechnology

HURA Stock Forecast: TuHURA Biosciences, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$1.93
−2.53% on the day

The 4 Wall Street analysts covering TuHURA Biosciences, Inc. hold a median 12-month price target of $8 — +314.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 18 of 100 as at 8 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$124.3M
Ticker Nerd rank
18 / 100
Median analyst target
$8.00
Analysts covering
4
Revenue$0.0
Operating income−$8.8M
Net income−$9.2M
Free cash flow−$8.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−2.5%
1M
−9.0%
YTD
+155.0%
1Y
−26.1%
From 52W high
−38.7%
From 52W low
+338.6%
$0.44
$3.15
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

HURA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores TuHURA Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
18 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
73
Value
70
Accruals
45
Revisions
41
Growth
24
Quality
20
Volatility
19
Momentum
18
Issuance
7

Size (73): Smaller than most of the companies we track.

Issuance (7): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

HURA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on HURA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00Jan 26Apr 26Jul 26Oct 26HURAHigh $10.00Median $8.00Low $6.20

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
4 Buy0 Hold0 Sell
Low $6.20Median $8.00High $10.00

The green dot is the last close — the median target sits +314.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
18 Aug 2026CitizensReiteratesMarket Outperform$9.00
27 Apr 2026CitizensInitiatesMarket Outperform—
27 Apr 2026CitizensInitiatesMarket Outperform$9.00
3 Feb 2026HC Wainwright & Co.ReiteratesBuy—
9 Jan 2026HC Wainwright & Co.ReiteratesBuy—
14 Nov 2025Maxim GroupMaintainsBuy—
16 May 2025HC Wainwright & Co.ReiteratesBuy—
3 Apr 2025HC Wainwright & Co.MaintainsBuy—
3 Mar 2025HC Wainwright & Co.InitiatesBuy—
19 Dec 2024Rodman & RenshawInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. HURA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

HURA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, TuHURA Biosciences, Inc. returned −26.1% against +16.2% for the S&P 500, dividends included.

HURA vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Jan 26Apr 26Jul 26Oct 26HURAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

HURA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

TuHURA Biosciences, Inc. (HURA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−3.1×

Cheaper than 88% of US stocks

Price / sales
—
Price / book
6.8×

Cheaper than 14% of US stocks

EV / EBITDA
−4.3×

Cheaper than 78% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−161.4%

Higher than 9% of US stocks

Return on assets
−58.4%

Higher than 6% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

TuHURA Biosciences, Inc. (HURA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • TuHURA Biosciences, Inc. has a market value of $124.3M and an enterprise value of $132.7M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$30.6M.

  • Free cash flow in the twelve months to 30 June 2026: −$29.9M.

  • TuHURA Biosciences, Inc. spent $8K on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 63.7M.

  • Trailing P/E: −3.1×; forward P/E: −3.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • TuHURA Biosciences, Inc. employs 22 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 9 Oct 2026

Data provided by Twelve Data

Peers

HURA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
HURATuHURA Biosciences, Inc.$124.3M
18
COYACoya Therapeutics, Inc.$117.1M
64
FHTXFoghorn Therapeutics, Inc.$116.6M
40
TNYATenaya Therapeutics, Inc.$117.8M
32
VTVTvTv Therapeutics, Inc.$118.5M
77
ENGNenGene Therapeutics, Inc.$114.9M
18
HUMAHumacyte, Inc.$120.6M
18

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own TuHURA Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest HURA news & analysis

TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology

PRNewsWire · 5 Oct 2026positive

TuHURA Biosciences announced that the U.S. Patent and Trademark Office has issued a key U.S. patent covering its Delta Opioid Receptor (DOR) antibody drug conjugate (ADC) technology. The patent also discloses additional uses beyond ADCs, including autologous or allogeneic adoptive cellular immunotherapies such as CAR-T, Tregs, or TIL cell therapies.

Why it matters — This patent strengthens TuHURA's intellectual property protection for its DOR ADC technology and its potential expansion into cell-based immunotherapies, which could broaden the company's therapeutic scope beyond its current Phase 3 pipeline.

TuHURA Biosciences Receives FDA "Study May Proceed" Notice and IND Clearance for the Evaluation of its TBS-2025 VISTA-Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood-Related Cancers

PRNewsWire · 14 Sept 2026positive

TuHURA Biosciences announced that the FDA has issued a "Study May Proceed" notice and cleared the company's Investigational New Drug application for TBS-2025, a VISTA-inhibiting antibody being evaluated for molecularly defined subsets of acute myeloid leukemia and other blood-related cancers.

Why it matters — This regulatory clearance allows TuHURA to expand its pipeline beyond its Phase 3 immuno-oncology work into a new area, advancing development of a novel VISTA-inhibiting antibody for blood cancers.

TuHURA Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference

PRNewsWire · 8 Sept 2026neutral

TuHURA Biosciences announced it will present at the H.C. Wainwright 28th Annual Global Investment Conference. The company, a Phase 3 immuno-oncology firm developing therapeutics to overcome resistance to cancer immunotherapy, made the announcement on September 8, 2026.

Why it matters — A presentation at a major investment conference gives HURA watchers an opportunity to hear directly from the company's leadership about its progress.

TuHURA Biosciences Highlights Phase III IFx Push, AML Trial Plans at Canaccord

MarketBeat · 14 Aug 2026positive

TuHURA Biosciences presented its late-stage immuno-oncology pipeline at the Canaccord Genuity Growth Conference, detailing an ongoing Phase III study of IFx in first-line advanced Merkel cell carcinoma, a planned AML trial for its VISTA-inhibiting antibody, and preclinical work on immune-modulating antibody-drug conjugates.

Why it matters — The presentation offers HURA watchers a clear update on the company's near-term clinical milestones and pipeline breadth.

FAQ

Frequently asked questions about HURA stock

What is the HURA stock price forecast for 2026-2027?

The 4 Wall Street analysts covering TuHURA Biosciences, Inc. have a median 12-month price target of $8, with estimates ranging from $6.2 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is HURA stock a buy right now?

Of the 4 analysts covering TuHURA Biosciences, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks TuHURA Biosciences, Inc. 18 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank HURA?

As at 8 Oct 2026, TuHURA Biosciences, Inc. ranks 18 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (73 of 100).

Will HURA stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +314.5% from the last close, and Ticker Nerd's factor model ranks TuHURA Biosciences, Inc. 18 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the HURA stock forecast for 2030?

No analyst covering TuHURA Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HURA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6.2 to $10 over the next 12 months.

How has HURA stock performed over the past year?

TuHURA Biosciences, Inc. returned -26.1% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does TuHURA Biosciences, Inc. do?

TuHURA Biosciences, Inc. is a clinical-stage immuno-oncology company focused on developing novel therapies designed to overcome resistance to cancer immunotherapy.

What is the latest news on HURA?

The most recent item we track (PRNewsWire, 5 Oct 2026): "TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology". TuHURA Biosciences announced that the U.S. Patent and Trademark Office has issued a key U.S. patent covering its Delta Opioid Receptor (DOR) antibody drug conjugate (ADC) technology. The patent also discloses additional uses beyond ADCs, including autologous or allogeneic adoptive cellular immunotherapies such as CAR-T, Tregs, or TIL cell therapies.

Company

About TuHURA Biosciences, Inc.

TuHURA Biosciences, Inc. is a clinical-stage immuno-oncology company focused on developing novel therapies designed to overcome resistance to cancer immunotherapy. The company’s current pipeline centers on immune-modulating product candidates, including IFx-2.0, an innate immune agonist intended to enhance responses to checkpoint inhibitors, and additional technologies aimed at addressing both primary and acquired resistance in the tumor microenvironment. TuHURA Biosciences also works on personalized cancer vaccines and bi-functional antibody-drug conjugates that target immune-suppressing cells linked to treatment resistance. Based in Tampa, Florida, TuHURA Biosciences operates in the biotechnology and oncology drug development sectors, where its programs are intended to support combination approaches for difficult-to-treat cancers and advance late-stage clinical research in immunotherapy.

CEO Dr. James A. Bianco M.D. · 22 employees · United States · https://www.tuhurabio.com